Frank E. Thomas's most recent trade in Larimar Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $5 . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 27 Feb 2026 | 5,000 | 7,000 | - | 5 | 25,000 | Common Stock |
| Spero Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 14 Feb 2024 | 2,000 | 2,000 | - | 11 | 22,000 | Common Stock |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 8,300 | 8,300 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 8,300 | 8,300 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 2,214 | 2,214 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Larimar Therapeutics Inc | Frank E. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 8,300 | 8,300 | - | - | Stock Option (right to buy) |